[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Aims& Scopes
Journal News
Articles archive::
All Issues
Current Issue
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
Authors Guideline
Call for Papers
Submission Instruction
Review Process
Research Ethics Statements
Ethical issues
Author Complaint Process
For Reviewers::
Reviewers Section
Subscription::
Registration Information
Subscription Form
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
FAQ
Top 10 contents
Inform to friends
::
Google Scholar Metrics

Citation Indices from GS

AllSince 2020
Citations68093459
h-index2719
i10-index19677
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE
..
:: Volume 32, Issue 6 (2-2025) ::
Journal of Ilam University of Medical Sciences 2025, 32(6): 84-96 Back to browse issues page
Breast Cancer Treatment in Balb/C Mice Using Dendritic Cells
Nowruz Delirezh1 , Akram Zangeneh * 2, Sanaz Sheikhzadeh1 , Naser Abbasi3
1- Dept of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran
2- Dept of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran , akramzangenehdr@gmail.com
3- Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran
Abstract:   (261 Views)
Introduction:  A fourth of all cancers in women in the country are breast cancer, making it the most common and fatal cancer in women. Some novel approaches are being implemented to reduce the impact of cancer. Thus, this study was conducted to treat breast cancer using dendritic cells in mice.
Materials & Methods: The study used the 4T1 cell line to induce breast cancer in Balb/C mice. After tumor induction, the mice were divided into three groups: healthy control, tumor control, and dendritic cell-treated groups. After developing palpable tumors, each group was treated with one million dendritic cells twice at a two-week interval. Body weight, tumor weight, and breast tissue samples were taken for pathological examination. Cells were photographed during the 9-day dendritic cell culture period. One-way analysis of variance (ANOVA) and Duncan's test were used in SPSS V.24 to analyze the data at the 0.05 significance level.
Results: In the dendritic cell treatment group, the ratio of tumor weight to body weight went down, and the amount of tumor weight loss was balanced out compared to the tumor control group. The dendritic cell receiving group also had a lot more tumor growth inhibition. The dendritic cell-treated group showed an increase in the number of immune cells in the tumor tissue.
Conclusion: Treatment with dendritic cells for the treatment of breast tumors enhances the immune response against the tumor.

 
Keywords: Dendritic Cells, Breast Tumor, 4T1
Full-Text [PDF 1549 kb]   (118 Downloads)    
Type of Study: Research | Subject: immunology
Received: 2024/09/14 | Accepted: 2024/10/15 | Published: 2025/02/3
References
1. Adan A, Alizada G, Kiraz Y, et al. Flow cytometry: basic principles and applications. Crit Rev Biotechnol 2017; 37: 163-76. doi: 10.3109/07388551.2015.1128876.
2. Aghaabbasi K, Hassani Kumleh H, Askari N, et al. Anticancer activity of Blepharis persica seed hydroalcoholic extract on (MCF-7) human breast cancer and (LNCaP) prostate cancer cell lines and its synergistic effect with doxorubicin. JCT 2018; 9: 206-21. doi: 10.52547/JCT.9.3.206.
3. Isetta AM, Fornasiero MC, Ferrari M, Trizio D. Immunosuppressive activity of 4'-iodo-4'-deoxy-doxorubicin on humoral and cell mediated immune responses in mice: comparison with doxorubicin. Int J Immunopharmacol 1990; 12: 665-73. doi: 10.1016/0192-0561(90)90104-u.
4. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006;127: 905-15. doi: 10.1016/j.cell.2006.0 9.042.
5. Asadi M, Taghizadeh S, Kaviani E, et al. Caspase-3: Structure, function, and biotechnological aspects. Biotechnol Appl Biochem 2022; 69:1633- 45. doi: 10.1002/bab.2233.
6. Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides 2015; 72: 4-15. doi: 10.1016/j.peptides.2015.04.012.
7. Yousefi Sadeghloo A, Khorsandi K, Kianmehr Z. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells. Photochem Photobiol Sci 2020; 19:1580-9. doi: 10.1039/d0pp00132e.
8. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther 2015; 14: 769-78. doi: 10.1158/1535-7163.MCT-14-0926.
9. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019; 120: 6-15. doi: 10.1038/s41416-018-0328-y.
10. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365-72. doi: 10.1093/jnci/94.18.1365.
11. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 2020; 21:3233. doi: 10.3390/ijms21093233.
12. Chen S, Lv M, Fang S, et al. Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes. Int J Biol Macromol 2018; 113: 1182-7. doi: 10.1016/j.ijbiomac.2018.02.034.
13. Yang CY, Liu HW, Tsai YC, Tseng JY, Liang SC, Chen CY, et al. Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer. Cancer Biol Ther 2015;16: 1641-50. doi:10.1080/15384047.2015.1095397.
14. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 2016; 539:443-7. doi: 10.1038/nature20554.
15. De Vera AA, Gupta P, Lei Z, et al. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Lett 2019; 442:91-103. doi: 10.1016/j.canlet.2018.10.020.
16. Dobosz P, Stępień M, Golke A, Dzieciątkowski T. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. Int J Mol Sci 2022;23: 2847. doi: 10.3390/ijms23052847.
17. Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol 2022; 221: e202201159. doi: 10.1083/jcb.202201159.
18. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020; 5:28. doi: 10.1038/s41392-020-0134-x.
19. Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget 2015;6: 41600-19.doi: 10.18632/oncotarget.6113.
20. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci 2021; 22:12827. doi: 10.3390/ijms222312827.
21. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J Drug Target 2011; 19:281-92. doi: 10.3109/1061186X.2010.499463.
22. Gibbert K, Schlaak JF, Yang D, et al. IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol 2013; 168: 1048-58.doi: 10.1111/bph.12010.
23. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, et al. Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen. Am J Reprod Immunol 2011; 65: 597-609. doi: 10.1111/j.1600-0897.2010.00968. x.
24. Harshitha R, Arunraj DR. Real-time quantitative PCR: A tool for absolute and relative quantification. Biochem Mol Biol Educ 2021; 49: 800-812. doi: 10.1002/bmb.21552.
25. Hashimoto N, Nagano H, Tanaka T. The role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and lifestyle-related diseases. Endocr J 2019; 66:485-96. doi: 10.1507/endocrj. EJ18-0565.
26. Hayrapetyan H, Tran T, Tellez-Corrales E, Madiraju C. Enzyme-Linked Immunosorbent Assay: Types and Applications. Methods Mol Biol 2023; 2612: 1-17.doi: 10.1007/978-1-0716-2903-1_1.
27. Hong DS, Postow M, Chmielowski B, et al. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res 2023;29: 2210-19.
28. Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, Liu W, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer 2022; 21:45. doi: 10.1186/s12943-022-01515-x.
29. Huo W, Yang X, Wang B, Cao L, Fang Z, Li Z, et al. Biomineralized hydrogel DC vaccine for cancer immunotherapy: a boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials 2022; 288: 121722. doi: 10.1016/j.biomaterials.2022.121722.
30. Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci 2020; 25:1058-109. doi: 10.2741/4847.
31. Jinmiao Lu, Nana Wei, Shilan Zhu, et al. Exosomes Derived from Dendritic Cells Infected with Toxoplasma gondii Show Antitumoral Activity in a Mouse Model of Colorectal Cancer. Front Oncol 2022; 12: 899737.doi: 10.3389/fonc.2022.899737.
32. Jozefczuk J, Adjaye J. Quantitative real-time PCR-based analysis of gene expression. Methods Enzymol 2011;500: 99-109. doi: 10.1016/B978-0-12-385118-5.00006-2.
33. Kaneda MM, Messer KS, Ralainirina N, et al, PI3Kγ is a molecular switch that controls immune suppression. Nature 2016; 539: 437- 42.doi: 10.1038/nature19834.
34. Ling SP, Ming LC, Dhaliwal JS, et al. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Cancers (Basel) 2022; 14:5205. doi: 10.3390/cancers14215205.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

Ethics code: IR-UU-AEC-3/40

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Delirezh N, Zangeneh A, Sheikhzadeh S, Abbasi N. Breast Cancer Treatment in Balb/C Mice Using Dendritic Cells. J. Ilam Uni. Med. Sci. 2025; 32 (6) :84-96
URL: http://sjimu.medilam.ac.ir/article-1-8404-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 32, Issue 6 (2-2025) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.15 seconds with 41 queries by YEKTAWEB 4680